ArticleOncology reports2026
Stable overexpression of Nup88 enhances HeLa cell migration through independent regulation of Kif7 and Gli1.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated expression of nucleoporin (Nup) 88 is often observed in various types of cancer and correlates with tumor grade. However, the underlying molecular mechanism by which Nup88 induces cancer malignancy remains unclear. The present study showed that stable overexpression of Nup88 in HeLa cells enhanced cell migration by modulating the expression of kinesin family member (Kif) 7 and glioma‑associated oncogene homolog (Gli) 1. The expression level of Kif7, a negative regulator of the Hedgehog (Hh) pathway acting through the processing of Gli2 and Gli3, was markedly reduced at both the mRNA and protein levels in Nup88 overexpressing HeLa cells. The reduced expression of Kif7 was restored by treatment with a DNA methylation inhibitor, suggesting epigenetic regulation. Co‑overexpression of a truncated Kif7 (514‑1343 aa), which possesses a large part of the Gli2 binding domain, suppressed the Nup88‑induced migration, suggesting that the downregulation of Kif7 contributed to the enhanced cell migration. In parallel, Gli1 expression was elevated through activation of the MEK‑ERK pathway and its knockdown markedly suppressed Nup88‑induced cell migration. Although both Kif7 and Gli1 are components of the Hh pathway, neither the knockdown of Kif7 nor the overexpression of Gli1 affected the expression of the other. Instead, the truncated Kif7 (514‑1343 aa) physically interacted with Gli1, suggesting that Kif7 suppressed enhanced migration by inhibiting Gli1 function. These findings revealed that Nup88 promotes cell migration by modulating the expression of Kif7 and Gli1, providing new insight into the mechanism of Nup88‑driven malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.